1147531-02-9

Basic information

• Product Name: (2-broMo-6-nitrobenzyloxy)(tert-butyl)diMethylsilane
• Synonyms: (2-broMo-6-nitrobenzyloxy)(tert-butyl)diMethylsilane
• CAS NO: 1147531-02-9
• Molecular Formula: C₁₃H₂₀BrNO₃Si
• Molecular Weight: 346
• Mol File: 1147531-02-9.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (2-broMo-6-nitrobenzyloxy)(tert-butyl)diMethylsilane(CAS DataBase Reference)
• NIST Chemistry Reference: (2-broMo-6-nitrobenzyloxy)(tert-butyl)diMethylsilane(1147531-02-9)
• EPA Substance Registry System: (2-broMo-6-nitrobenzyloxy)(tert-butyl)diMethylsilane(1147531-02-9)

Safety Data

• Hazardous Substances Data: 1147531-02-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(2-bromo-6-nitrobenzyloxy)(tert-butyl)dimethylsilane is used as a reagent in organic synthesis for various transformations, such as cross-coupling reactions and nucleophilic substitutions. Its unique structure and reactivity make it a versatile building block for the synthesis of pharmaceuticals, agrochemicals, and materials science applications.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (2-bromo-6-nitrobenzyloxy)(tert-butyl)dimethylsilane is used as a key intermediate in the synthesis of complex organic molecules with potential therapeutic properties. Its silicon-containing moiety provides stability and versatility for the design of new pharmaceutical compounds with specific therapeutic targets.
Used in Agrochemical Industry:
(2-bromo-6-nitrobenzyloxy)(tert-butyl)dimethylsilane is also used in the agrochemical industry as a precursor for the synthesis of novel agrochemicals with improved efficacy and selectivity. Its unique reactivity allows for the development of new compounds with targeted pest control properties.
Used in Materials Science:
In materials science, (2-bromo-6-nitrobenzyloxy)(tert-butyl)dimethylsilane is utilized for the design and synthesis of new materials with specific properties. Its silicon-containing moiety can provide stability and versatility, enabling the development of materials with tailored characteristics for various applications, such as coatings, adhesives, and polymers.

Upstream product

• 861106-90-3 2-bromo-6-nitrobenzyl acetate 
• 58579-54-7 3-bromo-2-(bromomethyl)-1-nitrobenzene 
• 861106-91-4 (2-bromo-6-nitro-phenyl)-methanol 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 1147531-04-1 3-bromo-2-[[tert-butyl(dimethyl)silyl]oxymethyl] aniline 
• 1198765-16-0 2-[3-bromo-2-(tert-butyldimethylsilanyloxymethyl)phenyl]-6-cyclopropyl-2H-isoquinolin-1-one 

Relevant articles and documents

Novel Bruton's tyrosine kinase inhibitor as well as preparation method and application thereof

The invention relates to a reversible novel Bruton's tyrosine kinase inhibitor which comprises a compound of a formula (I) as shown in the specification, and a stereisomer, a aquo-complex, a solvent compound, a pharmaceutically acceptable salt, an eutectic crystal or a predrug of the compound. The invention further relates to a preparation method of the compound and a method and the application ofthe novel compound in inhibiting BTK (Bruton's Tyrosine Kinase) kinase activity and mutant BTK kinase activity.

Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis

Bruton's tyrosine kinase (BTK) is a promising drug target for the treatment of multiple diseases, such as B-cell malignances, asthma, and rheumatoid arthritis. A series of novel aminotriazines were identified as highly selective inhibitors of BTK by a scaffold-hopping approach. Subsequent SAR studies of this series using two conformationally different BTK proteins, an activated form of BTK and an unactivated form of BTK, led to the discovery of a highly selective BTK inhibitor, 4b. With significant efficacy in models in vivo and good ADME and safety profiles, 4b was advanced into preclinical studies.

ISOQUINOLONES AS BTK INHIBITORS

The present invention encompasses compounds of the formula (I) wherein the groups R1, R2, R3, R4 and R5 are defined herein, which are suitable for the treatment of diseases related to Bruton's tyrosine kinase (BTK), and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.

Structure-based drug design of RN486, a potent and selective Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis

Structure-based drug design was used to guide the optimization of a series of selective BTK inhibitors as potential treatments for Rheumatoid arthritis. Highlights include the introduction of a benzyl alcohol group and a fluorine substitution, each of which resulted in over 10-fold increase in activity. Concurrent optimization of drug-like properties led to compound 1 (RN486) (J. Pharmacol. Exp. Ther. 2012, 341, 90), which was selected for advanced preclinical characterization based on its favorable properties.

SUBSTITUTED 1H-PYRROLOPYRIDINONE DERIVATIVES AS KINASE INHIBITORS

The present invention provides novel substituted 1H-Pyrrolopyridinone derivatives of formula (1) as protein kinase inhibitors, in which R1, R2, R3, R4, R5, R6 and 'p' have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting kinase enzyme, more particularly BTK enzyme. The present invention also provides methods for synthesizing and administering the kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF

Pyridone and pyrazinone compounds of Formula (I) including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

BTK protein kinase inhibitors

This application discloses pyridine and pyrimidine compounds according to formula I wherein R1, R2, R3, R4, R5, X1 and A are as described herein which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of formula I and at least one carrier, diluent or excipient.